Category: Pharma & Biotech

Veritas Pharma Enters Binding Letter of Intent to Secure ACMPR License and Cannabis Growing Facility

SHARE THIS POST VANCOUVER, November 18, 2017- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”), an emerging-stage pharmaceutical and IP development company, is pleased to announce that it has signed a Binding Letter of Intent with 906474 Alberta Ltd. (“906474”)subject to regulatory authority to acquire 100% ownership of Sechelt Organic Marijuana Corp. (“SOM”), free and clear of all liens, charges and encumbrances in exchange for $800,000 payable in shares of Veritas (“Veritas Shares”) priced at the last trading day immediately preceding the Closing (the “Purchase Price”). Veritas is also issuing to 906474 Special Warrant Shares which would entitle 906474 to additional shares of Veritas equal to $800,000 less the current market price of the Veritas Shares times the market price on last trading day immediately following the 4 month holding period. SOM, currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada and, since July 4, 2014, has had an application with Health Canada to become a licensed producer under the ACMPR. Dr. Lui Franciosi, CEO, Veritas Pharma comments, “This is a win-win scenario for Veritas and its shareholders. We believe this transaction is both tactical and value driven. Further and most importantly, it is representative of the steps we will take to secure and maximize our position along the medical marijuana supply chain. We are making great strides...

Read More

InMed to Present at Cannabis-Based Science & Medicine Conference

SHARE THIS POST Vancouver, BC – November 16, 2017 – InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at the Biopharma Forum on ‘Cannabis-Based Science & Medicine’ conference on Thursday, November 30th and Friday, December 1st, 2017 in Denver, CO. Dr. Sazzad Hossain, InMed’s Chief Scientific Officer, will be presenting a lecture entitled “Epidermolysis to Glaucoma – Identifying Pathology Candidates for Cannabis-Based Treatments.” This presentation will highlight InMed’s internal process of identifying disease targets for treatment with therapeutic cannabinoid compounds, developing tissue-specific delivery formulations, and innovative approaches to addressing regulatory challenges with cannabinoid-based therapies. More information on this conference, organized by CBI – a division of UBM, is available at: http://www.cbinet.com/conference/pc17091 About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com. Contact: InMed Pharmaceuticals Inc. Chris Bogart Investor Relations T: 604.669.7207 E: chris@inmedpharma.com TroyFlowers Author description...

Read More

Veritas and Cannevert Hires the Essèntium Group as Their Agent in Puerto Rico USA

SHARE THIS POST November 14, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces that the Company through its research arm, Cannevert Therapeutics Ltd. (“CTL”) has hired the Essèntium Group LLC, a leading consulting firm, as their agent to provide advice on clinical investigators and licensed medical cannabis producers to assist in the implementation of a clinical trial of a cannabis strain in the US territory of Puerto Rico. Veritas CEO, Dr. Lui Franciosi stated, “We are pleased to have this group help us with our mission of establishing the therapeutic potential of Cannevert’s cannabis strains. Although the people of Puerto Rico have endured a significant weather event this past September, they have demonstrated a will to immediately rebuild for the better. Over the years, this territory has been an active player within pharmaceutical industry with an abundance of expertise and infrastructure that Veritas will take advantage.” Dr. Franciosi goes on to say, “They have numerous licensed producers of medical cannabis with whole new varieties that are of great interest to us.” Puerto Rico is one of the world’s best known pharmaceutical production and development centers with a growing biotech presence. Most of the biggest pharmaceutical companies have used this US territory as a manufacturing or outsourcing base due to its established infrastructure, highly skilled labour force, popular tax...

Read More

Veritas Pharma Initiates Cancer Research with Dr. Dmitri Petchkovski

SHARE THIS POST VANCOUVER, British Columbia, Nov. 14, 2017 — Veritas Pharma Inc. (CSE:VRT); (OTC:VRTHF); and (Frankfurt:2VP), (“Veritas” or the “Company”) announces that it has initiated a cancer research project to assess the effects of several human cancer cell lines against select cannabis strains, along with standard clinical chemotherapeutic drugs for comparison. The Company has engaged Dr. Dmitri Petchkovski of Fibroblast Consulting in Vancouver, Canada to specifically investigate lung, prostate, colon, breast, and melanoma cancer cell lines. Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”) will provide Dr. Petchkovski with the required strains and oversee the implementation of this project. Veritas CEO, Dr. Lui Franciosi stated, “We are fortunate to obtain Dr. Petchkovski’s expertise, who will now begin the important task of scientifically determining the potential anticancer properties of Cannevert’s cannabis strains. Cancer is a disease that has touched many people and we want to provide physicians and patients with the best possible scientific evidence when prescribing cannabis as a treatment.” Cancer is a disease that results from changes in a group of normal cells within the body where they begin to grow uncontrollably to the point that a lump known as a tumor forms. If left untreated, these tumors spread into the surrounding normal tissue or to other parts of the body. According to Canadian Cancer Statistics 2017, there is an estimated 206,200 new cases of cancer and 80,800...

Read More

Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

SHARE THIS POST Executes Material Transfer Agreement with Yissum for Two Synthetic Agonists Synthesized by Professor Raphael Mechoulam AddThis TEL AVIV, Israel, Nov. 10, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem, for two synthetic cannabinoids synthesized by Raphael Mechoulam, Ph.D., Professor of medicinal chemistry at the university and Chairman of the Therapix Scientific Advisory Board. Therapix plans to initiate a preclinical study during the fourth quarter to evaluate the opioid-sparing effect of these compounds in a rat model. The opioid overuse epidemic in the United States was recently declared a public health emergency by President Donald Trump. According to Medical Care, prescription opioid overdose, abuse and dependence carries high costs for society with an estimated total economic burden of $78.5 billion in the United States alone. Nevertheless, for immediate relief of moderate-to-severe acute as well as chronic pain, opioids are frequently the treatment of choice due to their rapid onset and efficacy. However, due to their addictive nature and deleterious adverse events that may lead to lethal outcomes, there is a need to significantly reduce their effective therapeutic dose. Therapix Biosciences Download: Hi Res if (webDriver && webDriver.loadScripts) webDriver.loadScripts([{“type”:”script_url”,”url”:”js/jquery-webdriver.js”,”id”:”jquery-webdriver.js”},{“type”:”script_url”,”url”:”js/webdriver.js”,”id”:”webdriver.js”},{“type”:”script_url”,”url”:”js/wd_resize.js”,”id”:”wd_resize.js”},{“type”:”script_url”,”url”:”js/wd_distribute_height.js”,”id”:”wd_distribute_height.js”}]); Previous ItemNext Item Dr. Adi Zuloff-Shani, Chief Technology Officer at...

Read More

World Health Organization Explores International Rescheduling of CBD at Expert Committee Meeting

by Todd | Oct 26, 2017 | General, Medical Cannabis, Pharma & Biotech, Research | 0 comments October 26, 2017 Raul Elizalde to speak before WHO Expert Committee on Drug Dependence review of the psychoactivity of CBD. On November 6th, the World Health Organization’s (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence will begin a 5-day agenda set to determine the potential for harm or dependance of 16 different substances, including cannabidiol (CBD). Medical Marijuana, Inc. subsidiary HempMeds® will have a representative speaking before the committee on the first day regarding CBD. While WHO recognizes the medical use of certain substances is indispensable in the treatment of many conditions and that they should be available to patients for such purposes, the committee is also tasked with determining which substances should be regulated or banned internationally as scheduled drugs. WHO has a part in two of the United Nation’s central drug control conventions – the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic substances. WHO is responsible for conducting the medical, scientific, and public health evaluation of potentially harmful substances to determine the UN’s role in regulating them. This is done through the thirteen member Expert Committee on Drug Dependence (ECDD). The committee is made up of an international panel of experts in the field of drug addiction and abuse. The ECDD evaluates the dependence-producing...

Read More